In the United States, diffuse large B-cell lymphoma (DLBCL) has an incidence rate of 5.5-7.2 per 100,000 individuals, and a death rate of 1.7 per 100,000. Despite its prevalence, integrating the necessary diagnostic and prognostic markers…
Peripheral T-cell lymphomas (PTCLs) are a diverse collection of non-Hodgkin lymphomas that make treatment and patient-centered care challenging, and highlight the need for targeted therapies based on molecular and genetic profiling to enhance treatment efficacy and…
Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibition is the standard of care for patients with symptomatic myelofibrosis (MF); however, a significant number of hematologists/oncologists lack knowledge, competence, and confidence about JAK inhibitors (JAKis)…
The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This webcast will focus on emerging trial…